AC Immune Secures $4M Grant to Extend Parkinson's Trial
ACIU sits 32% above its 52-week low of $1.65 on light trading volume (0.4× avg).
Summary
AC Immune received a $4 million grant to extend its Phase 2 VacSYn trial for ACI-7104 in Parkinson's disease, enabling the collection of long-term safety and efficacy data.
Key Events · Product Development and Regulatory · ACIU
-
Grant Received
AC Immune secured a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation.
-
Trial Extension
The grant will fund a two-year extension of Part 1 of the Phase 2 VacSYn trial for ACI-7104 in early Parkinson's disease.
-
Long-Term Data Collection
This extension will allow for the assessment of long-term safety and efficacy, which is crucial for a chronic neurodegenerative disease.
-
Program Advancement
The funding supports the continued development of ACI-7104, an anti-alpha-synuclein active immunotherapy.
Analysis · ACIU · Life Sciences
This $4 million non-dilutive grant from The Vijay and Marie Goradia Charitable Foundation will fund a two-year extension of Part 1 of the Phase 2 VacSYn trial for ACI-7104 in early Parkinson's disease. This allows AC Immune to gather crucial long-term safety and efficacy data, which is particularly valuable for a chronic condition like Parkinson's, and strengthens the development pathway for this promising asset.
At the time of this filing, ACIU was trading at $2.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $221.9M. The 52-week trading range was $1.65 to $4.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.